Advertisement
UK markets open in 1 hour 9 minutes
  • NIKKEI 225

    37,210.74
    -868.96 (-2.28%)
     
  • HANG SENG

    16,167.83
    -218.04 (-1.33%)
     
  • CRUDE OIL

    84.53
    +1.80 (+2.18%)
     
  • GOLD FUTURES

    2,397.70
    -0.30 (-0.01%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • Bitcoin GBP

    50,225.10
    +755.98 (+1.53%)
     
  • CMC Crypto 200

    1,280.50
    +394.97 (+43.10%)
     
  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     
  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     

Teva Presented New Data on Fremanezumab: What You Should Know

Teva Presented New Data on Fremanezumab: What You Should Know

During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.